Industry3h ago
AI Accelerates Biologic Medicine Design
Engineered proteins form the basis of biologic medicines, yet most candidates fail during development. MIT Tech Review highlights how AI optimizes these protein structures to reduce costly trial-and-error cycles. These tools identify viable candidates faster than traditional synthetic chemistry. This shift lowers the financial barrier for researchers developing complex, targeted therapies.